Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> eradication: a prospective, multicentre, randomised controlled trial in Gansu Province, a high-resistance region of China.

ABSTRACT:

Background

Potassium-competitive acid blocker-based regimens, such as tegoprazan, have demonstrated promising efficacy for Helicobacter pylori eradication. In regions with high antibiotic resistance, such as Gansu Province, bismuth-containing quadruple therapy (BQT) remains the recommended first-line treatment. However, evidence on the efficacy and safety of high-dose tegoprazan-amoxicillin dual therapy (TA) remains limited.

Objectives

To compare the eradication rates and safety profiles of TA and BQT.

Design

Prospective, multicentre, randomised controlled trial.

Methods

Patients were enrolled from 10 centres across Gansu Province, China, between September and December 2024. Participants were randomised 1:1 to receive either BQT (esomeprazole 20 mg twice

SUBMITTER: Yang J 

PROVIDER: S-EPMC12618851 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature